Introduction
MS is a chronic autoimmune disorder affecting an estimated 2.5 million people worldwide. The pathological hallmarks for MS include perivascular T cell inflammation and disseminated demyelinating lesions. EAE is an inflammatory autoimmune disease, inducible in mice, that resembles human MS. As in MS, autoaggressive T cells traffic to the brain and spinal cord and induce CNS demyelination, leading to paresthesia, paraparesis, neuritis, and ataxia (1, 2) . Because of its similarity to human MS, EAE has been used as an animal model for proof of concept studies for MS therapy.
Cytokines play a pivotal role in the establishment and maintenance of autoimmune diseases. Numerous studies have established IL-12 as an important factor for the differentiation of naive T cells into IFN-g-producing Th1 cells, which are essential for cell-mediated immunity, including antimicrobial responses and tumor suppression (3) (4) (5) . Over the past decade, IL-12-driven Th1 cells were also shown to be essential for the induction of autoimmune diseases, primarily through investigations using IL-12p40 -/-mice and IL-12p40-neutralizing antibodies (6) (7) (8) (9) (10) (11) (12) (13) . However, mice lacking certain components of the Th1/IFN-g pathway (IL-12p35 -/-, IL-12b1 -/-, IFN-g -/-, IFN-gR -/-, and STAT1; R, receptor) are highly susceptible to inflammatory autoimmune diseases, indicating that these regulatory factors are not always required for disease induction (14) (15) (16) (17) (18) (19) . Yet other Th1 signaling components, such as STAT4 and T-bet, are essential for autoimmune pathogenesis (19, 20) . These findings suggest that another T cell population in addition to the IFN-g-producing T cells may also play a role in CNS autoimmune pathogenesis. The recent discovery of IL-23 - a cytokine that shares the p40 subunit with IL-12 - has since prompted reevaluation of the role of IL-12/Th1 response in autoimmunity (21, 22) . Using genetic approaches, studies have demonstrated that IL-23 rather than IL-12 is required for the development of spontaneous as well as adjuvant-induced autoimmune diseases such as EAE, collagen-induced arthritis (16, 17, (23) (24) (25) , and inflammatory bowel disease (26) . It has recently been shown that while IL-12 is required for the development of IFN-g-producing T cells, IL-23 promotes the expansion of a population of encephalitogenic T cells that produces IL-17A, IL-17F, IL-6, and TNF but not IFN-g or IL-4, suggesting that these cells represent a novel T cell subset (25) . We now show that these IL-17-producing cells are not dependent on T-bet and STAT1 transcription factor and that functional blockade of IL-23 can prevent induction of EAE and reverse established disease. We also studied the mechanisms of protection of IL-23-specific blockade during multiple stages of disease pathogenesis. Our results show that early anti-IL-23p19 treatment reduces encephalitogenic T cell and inflammatory myeloid cell invasion into the CNS and that treatment during active disease prevents epitope spreading of CD4 + T cells and inhibits subsequent disease relapse.
Results

Anti-IL-23 treatment prevents acute and relapsing EAE. IL-23-deficient
mice are highly resistant to autoimmune diseases, including EAE, collagen-induced arthritis, and inflammatory bowel disease (23) (24) (25) . However, this genetic resistance to autoimmune inflammation does not predict whether neutralizing the function of IL-23 can ameliorate ongoing disease. To determine the therapeutic efficacy of IL-23 blockade, we developed neutralizing anti-IL-23p19 antibodies that specifically inhibit the function of IL-23 but not IL-12 (Supplemental Figure 1 ; supplemental material available online with this article; doi:10.1172/JCI25308DS1) and tested the capacity of these mAbs to inhibit EAE. We also compared the efficacy of anti-IL-23p19 mAbs with anti-p40 mAbs, which neutralize the function of both IL-12 and IL-23. SJL mice were immunized with proteolipid protein 139-151 (PLP 139-151 ) peptide in CFA and injected with anti-IL-23p19 mAbs or anti-p40 mAbs at 1 day before and 6 days after immunization. Anti-IL-23p19 treatment effectively blocked both acute disease and EAE relapse, and histopathology showed absence of inflammatory cells in the spinal cord ( Figure  1 and Table 1 ). Consistent with previous reports, anti-p40 treatment was also remarkably effective (6, 8, 27) . Isotype treatment groups showed 100% EAE incidence and severe inflammatory cell infiltration into the spinal cord. This result is consistent with our previous studies demonstrating that targeted genetic disruption of IL-23 results in complete resistance to inflammatory autoimmune diseases (23) (24) (25) .
Anti-IL-23 therapy inhibits T cell and inflammatory macrophage invasion of the CNS. To understand how IL-23 regulates inflammatory
T cell and macrophage recruitment into the CNS, we analyzed the cytokine production profiles of mononuclear cells isolated from the brain and spinal cord before and after EAE onset. A normal CNS has undetectable to very few CD4 + T cells and CD45 hi CD11b + myeloid cells (28, 29) . During the course of EAE, T cells and inflammatory macrophages invade the CNS and produce a range of inflammatory cytokines (23, 28) . Ex vivo analysis of T cells infiltrating the CNS showed that, in addition to IFN-gproducing Th1 cells, IL-17-producing CD4 + T cells were also present ( Figure 2A and Table 2 ) (25) . To elucidate the roles of IFN-g, IL-17, and IL-23 in CNS inflammation, mice were treated with neutralizing antibodies at day -1 and day 6 after PLP-CFA immunization. Anti-IFN-g-treated mice had a severe form of the disease, with a 43% mortality rate. Anti-IL-17 treatment partially ameliorated EAE while anti-IL-23p19 completely protected mice from disease ( Figure 2 , B and C). Just before disease onset, the IL-17 serum level was highly elevated in EAE-susceptible IFN-gtreated mice. In contrast, the IL-17 level was near the limit of detection in the anti-IL-23p19-treated mice ( Figure 2D ). Even though IFN-g mRNA can be detected in the CNS during acute EAE (days 12 to 16) (30), our assay was not sensitive enough to detect serum IFN-g at this time point (not shown).
Histopathology of lumbar spinal cords from an anti-IL-23p19-treated group had undetectable or a few scattered leukocytes, as assessed by hematoxylin staining. Anti-IFN-g-treated mice showed intense inflammatory infiltration ( Figure 2E ). The anti-IL-17 antibody-treated mice showed an intensity of CNS-infiltrating cells similar to that of the isotype control group. In order to determine the number and the cytokine profile of CNS-infiltrating cells during EAE, we isolated mononuclear cells from the brain and spinal cord of mice before and after disease onset. Flow cytometric analysis showed that 7 days after myelin oligodendrocyte glycoprotein (MOG) priming (3 to 4 days before expected onset of clinical disease), anti-IL-23p19-treated mice showed a number (7000 to 9000) of IFN-g-producing cells similar to that of the isotype controls (Table 2 ). In contrast, the number of IL-17-producing cells was reduced in the anti-IL-23p19 treatment group (1800) compared with isotype controls (4000-6000). By day 9 after MOG priming (1 day before expected disease onset), the total number of CD4 + T cells and inflammatory macrophages in the EAE-resistant anti-IL-23p19 treatment group was less than that of isotype controls ( Figure 3A and Table 2 ). Accordingly, the number of IL-17, IFN-g, and TNF producers was also reduced by 2- to 5-fold compared with isotype controls (Table 2) . By day 12 after MOG priming (2 days after onset of clinical disease in control antibody groups), the EAE-resistant anti-IL-23p19-treated group had 6-fold fewer IL-17-producing T cells (15,000) and 2-fold fewer IFN-g (30,000) and TNF (210,000) producers (Table 2 and Figure  3 , B-D). In contrast, the EAE-susceptible anti-IFN-g-treated group had dramatically more inflammatory cells than the control group. There were 340,000 IL-17-producing cells, 190,000 IFN-g-producing cells, and 1,100,000 TNF-producing CD4 + T cells per CNS of anti-IFN-g-treated mice ( 
IL-23 drives a different signaling pathway.
We have shown that IL-23 appears to induce a T cell population that shares many functional characteristics with IFN-g-producing Th1 cells. As few as 100,000 IL-17-producing cells are capable of inducing CNS inflammatory responses leading to autoimmune encephalomyelitis (25) . To explore the signaling pathways of IL-12- versus IL-23-dependent T cells, we analyzed the function of T-bet and STAT1, which are known to promote type I immune responses. Lymph node cells from naive T-bet-deficient or WT control mice were cultured with anti-CD3 in the presence or absence of IL-23. IL-23p19-deficient lymph node cells do not produce IL-17 following antigenic or anti-CD3 stimulation (data not shown) (24) . In contrast, T-bet-deficient cells produced substantial levels (3000 to 4800 pg) of IL-17 following anti-CD3 stimulation. However, exogenous IL-23 did not further enhance IL-17 production, suggesting that T-bet may enhance IL-23-mediated IL-17 secretion ( Figure 4A ). Next, we compared the expression of T-bet in IL-12-driven Th1 cells and IL-23-driven IL-17-producing T cells. Cells cultured in the presence of IL-12 expressed higher levels of T-bet mRNA than IL-23 cultured cells ( Figure 4B ). In addition, IFN-g-producing Th1 cells expressed 5-fold more T-bet and 100-fold more TIM3, a Th1-specific membrane protein that regulates autoimmunity (32), compared with IL-17-producing cells ( Figure  4C ). These results indicate that T-bet is present in IL-17-producing cells. However, during differentiation of IL-17-producing cells, T-bet expression and function are reduced compared with Th1 cells. To determine whether STAT1 is also required for IL-23 to drive IL-17 production, lymph node cells from naive STAT1-defi- cient or WT control mice were cultured with anti-CD3 in the presence or absence of exogenous IL-23. Surprisingly, STAT1-deficient cells produced high levels of IL-17 following anti-CD3 stimulation ( Figure 4A ). Addition of exogenous IL-23 further enhanced IL-17 production in the STAT1-deficient cells. These results suggest that, while STAT1 is important for IFN-g signaling, it is not a critical factor for the IL-23/IL-17 immune pathway.
Therapeutic targeting of IL-23 inhibits spreading of PLP epitopes and prevents EAE relapse. We have demonstrated that administration of
anti-IL-23p19 mAbs blocked the invasion of inflammatory cells into the CNS and prevented EAE. Next, we determined whether targeting IL-23 can suppress and reverse ongoing disease. Anti-IL-23p19 treatment given just before (not shown) or on the day of disease onset ( Figure 5A and Table 3 ) did not inhibit the severity of acute disease but completely prevented EAE relapse. Antip40 treatment given on the day of disease onset also blocked EAE relapse but not acute disease. These results suggest that targeting IL-23 may influence regulatory mechanisms affecting development and/or recruitment of inflammatory cells to the CNS but cannot inhibit ongoing inflammatory effector mechanisms within the CNS. To understand how anti-IL-23 therapy inhibited disease relapse, we determined whether IL-23 blockade impeded PLP epitope spreading. In SJL mice, recent studies have shown that following PLP 139-151 immunization, 1 of the T cell epitopes that arises during disease relapse is directed against PLP [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] (33) . Therefore we tested T cell responses to PLP 139-151 and PLP [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] during initial EAE (day 11) and disease relapse (day 30). Mice were treated with anti-IL-23p19 or control mAbs just before disease onset. Draining lymph node (DLN) cells and CNS-infiltrating cells isolated from both the anti-IL-23p19 and isotype control mAb-treated groups showed PLP 139-151 but not PLP [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] response during the initial EAE attack ( Figure 5B ). In contrast, during disease relapse, the dominant response of CNS-infiltrating T cells from the isotype control group was PLP 178-191 whereas the DLN-T cell response was specific for PLP 139-151 but not PLP [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] ( Figure 5B ). This indicates that epitope spreading was restricted to the CNS and did not occur in the periphery, consistent with previous results (33) . Strikingly, mice treated with anti-IL-23p19 mAbs (day 8) showed a vigorous CNS PLP 139-151 response during the initial acute disease (day 11) but a complete lack of PLP 139-151 response and epitope spreading to PLP [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] (day 30). Thus, therapeutic targeting of IL-23 suppressed reactivation of the local response to PLP 139-151 as well as epitope spreading to PLP [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] , resulting in complete inhibition of disease relapse.
To further demonstrate the efficacy of anti-IL-23p19 therapy for relapse-remitting CNS inflammation, we initiated antibody treatment during recovery from acute EAE. Anti-IL-23p19 treatment at this time point significantly prevented disease relapse whereas isotype-treated mice had multiple rounds of EAE relapse ( Figure  6A and Table 3 ). Anti-p40 treatment, which inhibits both IL-12 and IL-23, also completely prevented disease relapse. In addition, anti-IL-17 treatment also delayed EAE relapse and reduced disease incidence and severity. Fifty days after immunization, spinal cord histopathology showed that both anti-IL-23p19- and antip40-treated groups had significantly fewer inflammatory foci than the isotype control groups (Table 3) . However, even though anti-IL-17 treatment blocked EAE relapse, it did not significantly reduce the number of infiltration foci, suggesting that this treatment does not alter inflammatory cell migration and/or expansion but may downregulate the effector function of inflammatory cells within the CNS.
We also analyzed proinflammatory gene expression of spinal cords following anti-IL-23p19, anti-IL-12/23p40, and anti-IL-17 therapy. Both anti-IL-23p19 and anti-IL-12/23p40 antibody treatment significantly blocked the induction of IFN-g, IL-1b, IL-6, IL-17, TNF, CCL6, MIG, and IP-10 gene expression compared with isotype-treated mice ( Figure 6B ). Anti-IL-17 treatment specifically reduced expression of IL-1, IL-6, and CCL6. Anti-IL-12/23p40 treatment but not anti-IL-23p19 treatment reduced mRNA expression of osteopontin (OPN). Specific blockade of IL-23 also resulted in a 10- to 100-fold reduction of macrophage- and dendritic cell-associated genes such as MDC, MCP-1, CXCL1, CXCL2, CCR1, MHC class II, CD11b, Mac 2, F4/80, CD86, CD14, TREM2, MYD88, and NADPhox gp91 compared with spinal cords of control-treated mice (not shown). These results suggest that targeting the IL-23/IL-17 immune pathway can prevent disease relapse in mice that already have active CNS lesions.
Discussion
The study of IL-12 and IL-23 regulation of immune responses has yielded important clues to identifying additional players in cellular immunity. We now know that, in addition to the IFN-gproducing Th1 cells, there is a second population of T cells that can drive autoimmune pathologies. Due to its prominent production of IL-17 and its proinflammatory nature, this novel T cell population has been termed Th (25, 34) , Th17 cells (35, 36) , or inflammatory Th cells (37) . An important question that needs to be addressed is the lineage relationship between the IFN-g- producing Th1 and Th IL-17 cells. There is agreement that IL-12 activation of STAT4 is necessary for optimal differentiation of naive T cells into IFN-g-producing Th1 cells. IFN-g then activates the STAT1 transcription factor, which enhances T-bet expression. T-bet activation is required for optimal IL-12Rb2 expression and IL-12 responsiveness in Th1 cells (19, (38) (39) (40) . One crucial question is why STAT4 and T-bet appear to be important for autoimmune disease induction while IL-12, IFN-g, and STAT1 signaling are not always required. The discovery of the IL-17-producing T cell population that does not depend on IL-12-IFN-g-STAT1 signaling has provided a partial explanation for the observed discrepancy in autoimmune disease models. We now know that STAT1 activation is not required for T cell response to IL-23 and subsequent IL-17 production ( Figure 4) . As the cells mature in the presence of IL-23, both T-bet and TIM3 - a potent Th1 cell-associated regulatory molecule (32, 41) - may be repressed due to the absence of IFN-g and STAT1 signaling. While IL-23p19-deficient mice do not produce detectable levels of IL-17 (24, 25) , lymph node cells from both T-bet-deficient and WT mice produce similar levels of IL-17 ( Figure 4A ), consistent with a recent report that IL-17-producing cells are present in T-bet-deficient mice (37) . The observation that IL-17-producing cells are present in EAE-resistant T-bet-deficient mice suggests that Th IL-17 cells are not sufficient to induce disease and that other T-bet-dependent factors and/or cell populations have important roles in disease pathogenesis. We also observed that addition of IL-23 to T-bet-deficient lymph node cell cultures did not further increase IL-17 production (Figure 4) , consistent with the notion that T-bet may influence IL-23 responsiveness during early development (42) . In addition, the presence of T-bet in cells is reminiscent of the discovery that both T-bet and GATA-3 are present in T cells during early differentiation and that T-bet interferes with the function of GATA-3, leading to preferential Th1 lineage commitment (43) . These findings suggest that T-bet may have complex regulatory roles - both positive and negative effects - during Th IL-17 development. Future work will elucidate how T-bet regulates transcription factors that promote Th IL-17 lineage development.
The current study suggests that one of the mechanisms of protection of anti-IL-23p19 therapy is associated with inhibition of encephalitogenic T cells. Intracellular cytokine analysis of draining lymph node cells from PLP-primed mice indicated that anti-IL-23p19 treatment reduced the number of IL-17-producing cells but not IFN-g-producing cells. Addition of anti-IL-23p19 mAbs to PLP 139-151 -stimulated DLN cell cultures also specifically reduced the percentage of IL-17-producing cells (Supplemental Figure 2) . During the early phase of EAE (3 to 4 days before clinical disease onset), there were fewer IL-17-producing cells entering the CNS of anti-IL-23p19-treated mice (Table 2) . At this time point, similar numbers of IFN-g-producing cells were found in both groups of mice. This specific reduction of CNS-infiltrating IL-17-producing cells may be explained by the hypothesis that anti-IL-23p19 treatment directly inhibited the expansion of IL-17-producing T cells. This is consistent with recent studies showing that IL-23 is required for the expansion of pathogenic IL-17-producing T cells (25) . Furthermore, the IFN-g/STAT1 signaling pathway is a potent negative regulator of IL-23/IL-17 immune responses (36, 37) .
Although CNS antigen-specific IFN-g-producing Th1 cells can transfer EAE to naive recipient mice, administration of anti-IFN-g We observed that therapeutic targeting of IL-23 during active EAE inhibited subsequent disease relapses. Two possible mechanisms that may explain this observation include inhibition of encephalitogenic epitope spreading and enhanced generation of Tregs. Miller and coworkers have recently demonstrated that local APC and/or dendritic cell activation of naive T cells within the CNS is required for encephalitogenic epitope spreading (33) . Our study showed that anti-IL-23p19 treatment during active disease did not ameliorate acute EAE; instead, it blocked PLP 139-151 -specific T cells within the CNS and epitope spreading to additional encephalitogenic epitopes such as PLP [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] . Interestingly, the protected mice still had PLP 139-151 -reactive cells in the peripheral lymphoid tissues. This finding suggests that the therapeutic action of anti-IL-23 for ongoing EAE is likely to occur within the target organ. We also determined whether Tregs are enhanced in anti-IL-23p19 mAb-treated mice. Analysis of lymph node cells and CNS-infiltrating cells showed little or no difference in the number of CD4 + CD25 + FoxP3 + cells in anti-IL-23p19 or isotype control mAb-treated mice (data not shown). Passive transfer of cells isolated from anti-p19-treated mice to PLP peptide-immunized mice did not confer protection from EAE, suggesting that anti-IL-23p19 treatment in the SJL model of EAE did not increase the number of FoxP3 + Tregs capable of inhibiting EAE relapse. Thus, these studies suggest that anti-IL-23p19 therapeutic inhibition of EAE relapse is mainly due to inhibition of encephalitogenic epitope spreading and recruitment of newly activated pathogenic T cells, possibly from the naive thymic emergent pool.
Other mechanisms of action of anti-IL-23p19 therapy are reducing the number of inflammatory myeloid cells invading the CNS and dampening the levels of monokines derived from macrophage and dendritic cells (e.g., IL-1, IL-6, TNF, MCP-1, MDC, CXCL1, CXCL2, CCR1, MHC class II, CD11b, Mac 2, F4/80, CD86, CD14, TREM1, MYD88, and NADPhox gp91). This myeloid cell invasion and the production of proinflammatory mediators are the driving forces behind CNS edema and demyelination - the pathological hallmarks of EAE and MS. Recent studies have demonstrated that the IL-23 receptor complex is expressed on a subset of inflammatory macrophages and dendritic cells (22) . IL-23 can induce ex vivo production of IL-1 and TNF by peritoneal macrophage (23) and enhance DTH responses mediated by the passive transfer of peptide-pulsed dendritic cells (47) . The direct effect of IL-23 on myeloid cell function was confirmed by our recent study demonstrating that anti-IL-23p19 treatment of T cell-deficient Rag KO mice completely prevented colitis induced by activated dendritic cells and macrophages (D.J. Cua and B. Mckenzie, unpublished observations). In addition, this myeloid cell-mediated colitis was only inducible in IL-12p35 × Rag double-KO mice but not IL-23p19 × Rag KO mice. This T cell-independent colitis model showed that IL-23 but not IL-12 directly regulates the capacity of dendritic cells to induce inflammatory bowel disease-like lesions. These findings have important implications as both Th1 (50, 51) . Anti-IL-17 administration prevented neutrophil accumulation in the lung following pulmonary LPS challenge (52) . In addition, administration of anti-IL-23p19 mAbs reduced LPS induction of IL-17 and lowered the number of circulating neutrophil (D.J. Cua, unpublished observations), consistent with the recently described neutrophil turnstile hypothesis proposed by Ley and coworkers (53) , which suggests that the IL-23/IL-17 immune axis is important for maintenance of neutrophil homeostasis. Thus, targeting IL-12 could affect IFN-g-mediated macrophage and CTL activation as well as induction of subclasses of antibody responses important for host defense. In contrast, targeting IL-23 will likely affect IL-17-dependent rapid neutrophil recruitment to sites of injury and inflammation.
It is well recognized that anti-p40 treatment is highly efficacious for inflammatory autoimmune disease models. Recent clinical data also indicate that anti-p40 therapy may be effective for the treatment of human autoimmune diseases such as psoriasis and Crohn disease (54, 55) . One potential issue with anti-p40 therapy is that it may inhibit both the classical IL-12/IFN-g and the newly described IL-23/IL-17 immune pathways as discussed above. Con-
Figure 5
Anti-IL-23 therapy inhibits PLP epitope spreading and relapsing EAE. (A) Average clinical score of mice treated with anti-IL-23p19 (clone MB490) or anti-p40 antibody on the day of EAE onset. The first antibody dose was given by the i.v. route at the first sign of clinical disease and the 2 subsequent doses by the s.c. route at days 7 and 14 after EAE onset. One of 3 experiments is shown. Disease relapse incidence and histopathology scores are shown in Table 3 . Arrows indicate the day of initial mAb treatment (day of disease onset). (B) Epitope spreading was determined by analysis of DLN cells or purified CNS mononuclear cells for response to PLP139-151 or PLP178-191 on either the day of disease onset or during disease relapse. Purified CNS mononuclear cells from mice treated with anti-IL-23p19 or isotype control mAbs were stimulated for 4 days with PLP peptides then pulsed with 3 Mice were immunized with PLP139-151 and treated with pertussis toxin at day 0. Mice received mAb treatment on the day of clinical paralysis onset or during remission from acute disease. Assessment of relapse clinical EAE includes the number of mice that develop disease relapse, the mean day of relapse onset among mice with clinical relapse ± SEM, and the mean clinical disease grade ± SEM of each treatment group. Spinal cord samples for histopathology were taken on days 52-54. Data shown are mean number of parenchymal and perivascular inflammatory foci ± SD. A P < 0.006, comparing anti-IL-23p19 versus mIgG1 by 2-tailed Student's t test; B P < 0.02, comparing anti-IL-12p40 versus rIgG2a by Student's t test; C P < 0.02, comparing anti-IL-23p19 versus mIgG1 by Student's t test; D P < 0.01, comparing anti-IL-12p40 versus rIgG2a by Student's t test; E P < 0.69, comparing anti-IL-17 versus rIgG1 by Student's t test.
Figure 6
Anti-IL-23 therapy during disease remission inhibits CNS expression of proinflammatory cytokines and prevents EAE relapse. (A) Average clinical score of mice given the first treatment dose of anti-IL-23p19 (clone MB490), anti-IL-17 (clone 1D10), or anti-p40 (clone C17.8) during disease remission. The first antibody dose (1 mg) was given by the i.v. route at day 18 after immunization and the 2 subsequent doses (1 mg/dose) by the s.c. route at 7 and 14 days after the initial treatment. Results from 1 of 2 experiments are shown. Details on incidence of disease relapse and histopathology scores are shown in 
